Ascletis Pharma Valuation
| ASCLF Stock | USD 1.04 0.12 13.04% |
Today, the firm appears to be fairly valued. Ascletis Pharma shows a prevailing Real Value of $1.06 per share. The current price of the firm is $1.04. Our model approximates the value of Ascletis Pharma from analyzing the firm fundamentals such as profit margin of (2.24) %, and Return On Equity of -0.0632 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Ascletis Pharma's price fluctuation is out of control at this time. Calculation of the real value of Ascletis Pharma is based on 3 months time horizon. Increasing Ascletis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ascletis pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Ascletis Pharma. Since Ascletis Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ascletis Pink Sheet. However, Ascletis Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.04 | Real 1.06 | Hype 1.04 | Naive 0.91 |
The real value of Ascletis Pink Sheet, also known as its intrinsic value, is the underlying worth of Ascletis Pharma Company, which is reflected in its stock price. It is based on Ascletis Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ascletis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ascletis Pharma helps investors to forecast how Ascletis pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ascletis Pharma more accurately as focusing exclusively on Ascletis Pharma's fundamentals will not take into account other important factors: Ascletis Pharma Total Value Analysis
Ascletis Pharma is presently expected to have takeover price of 116.15 M with market capitalization of 672.93 M, debt of 2.75 M, and cash on hands of 2.5 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ascletis Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
116.15 M | 672.93 M | 2.75 M | 2.5 B |
Ascletis Pharma Investor Information
About 67.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ascletis Pharma recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Ascletis Pharma's financial statements, Ascletis Pharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Ascletis Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ascletis Pharma has an asset utilization ratio of 2.72 percent. This implies that the Company is making $0.0272 for each dollar of assets. An increasing asset utilization means that Ascletis Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Ascletis Pharma Ownership Allocation
Ascletis Pharma holds a total of 1.09 Billion outstanding shares. Ascletis Pharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.02 percent of Ascletis Pharma outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ascletis Pharma Profitability Analysis
The company reported the revenue of 76.88 M. Net Loss for the year was (199.02 M) with profit before overhead, payroll, taxes, and interest of 39.17 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ascletis Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ascletis Pharma and how it compares across the competition.
About Ascletis Pharma Valuation
The pink sheet valuation mechanism determines Ascletis Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Ascletis Pharma. We calculate exposure to Ascletis Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ascletis Pharma's related companies.Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.
8 Steps to conduct Ascletis Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Ascletis Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Ascletis Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Ascletis Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Ascletis Pharma's revenue streams: Identify Ascletis Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Ascletis Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Ascletis Pharma's growth potential: Evaluate Ascletis Pharma's management, business model, and growth potential.
- Determine Ascletis Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Ascletis Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Ascletis Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ascletis Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.1 B | |
| Retained Earnings | -714.8 M |
Complementary Tools for Ascletis Pink Sheet analysis
When running Ascletis Pharma's price analysis, check to measure Ascletis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascletis Pharma is operating at the current time. Most of Ascletis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascletis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascletis Pharma's price. Additionally, you may evaluate how the addition of Ascletis Pharma to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |